Key Takeaways Puma Biotechnology posted Q3 adjusted EPS of $0.21, which topped estimates but fell from last year's$0.45.Q3 revenues of $54.5 million beat expectations but declined 32.3$220-$223 million, while increasing Nerlynx product sales outlook.Puma Biotechnology (PBYI) reported third-quarter 2025 adjusted earnings of 21 cents per share, which beat the Zacks Consensus Estimate of 9 cents. In the year-ago quarter, the compan ...